Bröms G, Kieler H, Ekbom A, et al. - Given that most anti‐tumour necrosis factor (anti‐TNF) agents are transferred across the placenta and may increase paediatric susceptibility to infections, researchers sought to evaluate the risk of paediatric infections after maternal anti‐TNF treatment. A population‐based cohort study in Denmark, Finland and Sweden 2006‐2013 in which 1,027 children born to women with rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis or inflammatory bowel disease, treated with anti‐TNF, and 9,346 children to women with nonbiologic systemic treatment, were contrasted to 1,617,886 children of the general population. An elevated risk of paediatric infections was associated with both anti‐TNF and non‐biologic systemic treatment. Reassuringly, however, the elevated risks were present in the third trimester, with a combination of treatments, irrespective of treatment, and were not persistent in the first 3 years of life. The results may suggest a true risk, but may also be due to unadjusted confounding by severity of the disease and healthcare‐seeking behaviour. This may, in turn, shift the risk-benefit equation towards continuing treatment even in the third trimester.